Trial Profile
A Phase 2/3, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Etoposide; Etoposide; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 10 Aug 2018 Status changed from active, no longer recruiting to completed.
- 27 May 2018 This trial has been completed in France (End date: 2018-04-05)
- 09 May 2018 This trial has been completed in Sweden (End date: 2018-04-05)